The above-reported ability of PPARs in modulating ALDH expression, confirmed also in rat hepatoma cells and human breast cancer cells [191,192], can represent a strategy to reduce the resistance to anticancer drugs acting through the formation of free radicals, as doxorubicin, or oxazaphosphorines, whose metabolic intermediates are catabolized by ALDH [193]. The gene discussed is LDHA; the disease is hepatocellular carcinoma.